Zagallo is a new hair loss and AGA medication that was recently approved on September 28, 2015. It is slated to go on sale by GlaxoSmithKline on June 13, 2016.
It is offered in 0.1mg and 0.5mg doses and is called, “Zagallo Capsule 0.1mg” or “Zagallo Capsule 0.5mg,” respectively. The main ingredient is dutasteride, classified as a 5-alpha-reductase enzyme blocker, the same category as finasteride, found in MSD’s Propecia. This is the same substance as that found in Avolve in Japan, which is prescribed for enlarged prostate and is more effective than Propecia at promoting hair on the hairline, front of the head, and top of the head. The name is derived from “Z” as the “ultimate” and AGA for androgenetic alopecia (male pattern baldness).
The product is consumed once a day and can be consumed with food. The interview form and additional documents ask about erectile dysfunction and decreased libido or sex drive. Further, given the possibility of initial hair loss, its unsuitability for women, the fact that it cannot be used while pursuing pregnancy, and the fact that PSA is halved when in use, blood transfusions cannot be performed.
The National Health Insurance price is as yet undecided, so pricing for this prescription will be announced soon. This is treated as at one’s own expense and is not covered by insurance.
We plan to continue prescribing Avolve going forward; those interested can elect to use Zagallo.
If you have not seen the effects you desired with Propecia, you can switch to Zagallo. Note that using Propecia and Zagallo in combination is atypical. Minoxidil works by a different mechanism, however, so using it in combination can yield greater benefits.